Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NASDAQ:RLMD NASDAQ:TKNO NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$9.37-4.2%$8.02$56.35▼$105.00$271.59M0.9512,438 shs156,303 shsRLMDRelmada Therapeutics$2.01$1.46$0.24▼$3.98$66.72M0.91378,108 shs222,853 shsTKNOAlpha Teknova$5.13-2.5%$4.88$3.94▼$10.37$274.53M0.41376,257 shs145,953 shsZURAZura Bio$3.21-6.4%$2.55$0.97▼$5.07$208.71M0.254.30 million shs1.07 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics-4.24%+3.19%+34.82%-1.06%-88.66%RLMDRelmada Therapeutics0.00%-1.47%+21.82%+248.35%-42.57%TKNOAlpha Teknova0.00%+3.43%+10.56%+20.14%-15.07%ZURAZura Bio0.00%-22.65%+56.59%+68.06%-29.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$9.37-4.2%$8.02$56.35▼$105.00$271.59M0.9512,438 shs156,303 shsRLMDRelmada Therapeutics$2.01$1.46$0.24▼$3.98$66.72M0.91378,108 shs222,853 shsTKNOAlpha Teknova$5.13-2.5%$4.88$3.94▼$10.37$274.53M0.41376,257 shs145,953 shsZURAZura Bio$3.21-6.4%$2.55$0.97▼$5.07$208.71M0.254.30 million shs1.07 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics-4.24%+3.19%+34.82%-1.06%-88.66%RLMDRelmada Therapeutics0.00%-1.47%+21.82%+248.35%-42.57%TKNOAlpha Teknova0.00%+3.43%+10.56%+20.14%-15.07%ZURAZura Bio0.00%-22.65%+56.59%+68.06%-29.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ARLMDRelmada Therapeutics 1.75Reduce$1.00-50.25% DownsideTKNOAlpha Teknova 2.67Moderate Buy$10.0094.93% UpsideZURAZura Bio 2.75Moderate Buy$11.60261.37% UpsideCurrent Analyst Ratings BreakdownLatest RLMD, ZURA, TKNO, and AVTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025ZURAZura BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025RLMDRelmada TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TKNOAlpha TeknovaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/30/2025ZURAZura BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.009/27/2025RLMDRelmada TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TKNOAlpha TeknovaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ZURAZura BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/19/2025ZURAZura BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$3.00 ➝ $2.008/15/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $16.008/15/2025ZURAZura BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.007/22/2025TKNOAlpha TeknovaStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$8.00(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ATKNOAlpha Teknova$37.74M7.27N/AN/A$1.55 per share3.31ZURAZura BioN/AN/AN/AN/A$2.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%11/10/2025 (Estimated)RLMDRelmada Therapeutics-$79.98M-$2.22N/AN/AN/AN/A-223.17%-180.41%11/6/2025 (Estimated)TKNOAlpha Teknova-$26.75M-$0.42N/AN/AN/A-55.24%-26.51%-18.40%11/6/2025 (Estimated)ZURAZura Bio-$45.39M-$0.70N/AN/AN/AN/A-49.11%-40.06%11/6/2025 (Estimated)Latest RLMD, ZURA, TKNO, and AVTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025RLMDRelmada Therapeutics-$0.04N/AN/AN/AN/AN/A11/6/2025Q3 2025ZURAZura Bio-$0.19N/AN/AN/AN/AN/A8/14/2025Q2 2025ZURAZura Bio-$0.19-$0.17+$0.02-$0.17N/AN/A8/7/2025Q2 2025RLMDRelmada Therapeutics-$0.25-$0.30-$0.05-$0.30N/AN/A8/7/2025Q2 2025TKNOAlpha Teknova-$0.1004-$0.07+$0.0304-$0.07$9.90 million$10.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78RLMDRelmada TherapeuticsN/A4.114.11TKNOAlpha Teknova0.175.874.70ZURAZura BioN/A8.408.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ARLMDRelmada Therapeutics45.24%TKNOAlpha Teknova13.81%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%RLMDRelmada Therapeutics20.70%TKNOAlpha Teknova12.50%ZURAZura Bio14.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableRLMDRelmada Therapeutics1033.19 million26.32 millionOptionableTKNOAlpha Teknova24053.51 million46.83 millionNot OptionableZURAZura Bio365.02 million55.77 millionOptionableRLMD, ZURA, TKNO, and AVTE HeadlinesRecent News About These CompaniesZura Bio Limited (NASDAQ:ZURA) Sees Significant Growth in Short InterestOctober 18 at 2:48 AM | marketbeat.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Zura Bio (NASDAQ:ZURA)October 16 at 2:37 AM | americanbankingnews.comZura Bio's (ZURA) Sell (D-) Rating Reiterated at Weiss RatingsOctober 14, 2025 | marketbeat.comLeerink Partners Reaffirms Their Buy Rating on Zura Bio (ZURA)October 13, 2025 | theglobeandmail.comZura Bio CEO Takes Medical Leave, Interim AppointedOctober 10, 2025 | msn.comIs Zura Bio’s (ZURA) Executive Severance Plan Hinting at Leadership Stability or Looming Funding Shifts?October 4, 2025 | finance.yahoo.comChardan Capital Maintains Zura Bio (ZURA) Buy RecommendationOctober 1, 2025 | msn.comZura Bio Implements Executive Severance Benefit PlanSeptember 30, 2025 | tipranks.comSeptember 2025's Promising Penny Stocks RevealedSeptember 30, 2025 | finance.yahoo.comChardan Capital Reiterates Buy Rating for Zura Bio (NASDAQ:ZURA)September 30, 2025 | marketbeat.comZura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by BrokeragesSeptember 26, 2025 | marketbeat.comZura Bio Unveils Updated Corporate PresentationSeptember 4, 2025 | tipranks.comZura Bio price target lowered to $2 from $3 at H.C. WainwrightAugust 19, 2025 | msn.comZura Bio price target lowered to $16 from $17 at OppenheimerAugust 15, 2025 | msn.comZura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate UpdatesAugust 14, 2025 | businesswire.comRobert Lisicki on Living Up to Zura Bio’s Heroic NamesakeJuly 31, 2025 | pharmexec.comP3 Penny Stocks With Market Caps Over $70M Worth WatchingJuly 18, 2025 | finance.yahoo.comZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 | finance.yahoo.comZura Bio Announces Chief Financial Officer TransitionJuly 1, 2025 | businesswire.comZura Bio shareholders approve board nominees and auditorMay 24, 2025 | investing.comZura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativaMay 21, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRLMD, ZURA, TKNO, and AVTE Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$9.37 -0.42 (-4.24%) As of 10/17/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Relmada Therapeutics NASDAQ:RLMD$2.01 0.00 (0.00%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$2.03 +0.02 (+1.00%) As of 10/17/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Alpha Teknova NASDAQ:TKNO$5.13 -0.13 (-2.47%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$5.12 0.00 (-0.10%) As of 10/17/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.Zura Bio NASDAQ:ZURA$3.21 -0.22 (-6.41%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.26 +0.05 (+1.56%) As of 10/17/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
